ReviewCureus2026
Chronic Thromboembolic Pulmonary Hypertension: A Narrative Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute pulmonary embolism (PE), which is chronically underdiagnosed. It is characterized by organized thromboembolic lesions within the pulmonary arteries, resulting in both obstruction of pulmonary arterial blood flow and pathologic small vessel remodeling. Patients present with dyspnea and decreased exercise tolerance; however, CTEPH patients are generally very comorbid, and these nonspecific symptoms often fail to initiate the diagnostic investigations. Late presentation results in poor outcomes with pulmonary hypertension and symptomatic right heart failure. Surgical treatment with pulmonary thromboendarterectomy is the gold standard treatment for CTEPH; however, only proximal arterial disease is surgically accessible. Over a third of patients are ineligible for surgery due to a significant burden of distal disease or comorbidities. Other treatment modalities, such as balloon angioplasty and medical therapies, play an important role in the management of these patients. Investigations for the diagnosis and treatment of CTEPH are extensive and require close multidisciplinary collaboration between medical, surgical, and imaging specialists. However, initiating the diagnostic investigations and referral process relies primarily on a high index of suspicion maintained by general practitioners, as early diagnosis is paramount to achieving successful outcomes in this cohort. The objective of this narrative review is to summarize the current knowledge and understanding of CTEPH, including its pathogenesis, presentation, diagnosis, current treatments, and outcomes. We also highlight current areas of uncertainty and ongoing research. Improving awareness and understanding of CTEPH will ultimately lead to better outcomes in the treatment of this disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.